Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
2009.
Current awareness: Pharmacoepidemiology and drug safety.
Pharmacoepidemiology and Drug Safety,
Vol. 18,
Issue. 10,
Nakamura, Masaru
and
Nagamine, Takahiko
2010.
Severe Hyperglycemia Induced by Olanzapine was Improved with a Recovery of Insulin Secretion after Switching to Risperidone and Introducing Insulin Therapy.
Internal Medicine,
Vol. 49,
Issue. 23,
p.
2635.
Shin, Lauren
and
Henderson, David C.
2010.
Pediatric Obesity.
p.
369.
Golubnitschaja, Olga
2010.
Time for new guidelines in advanced diabetes care: Paradigm change from delayed interventional approach to predictive, preventive & personalized medicine.
EPMA Journal,
Vol. 1,
Issue. 1,
p.
3.
Case, Michael
Treuer, Tamas
Karagianis, Jamie
and
Hoffmann, Vicki Poole
2010.
The potential role of appetite in predicting weight changes during treatment with olanzapine.
BMC Psychiatry,
Vol. 10,
Issue. 1,
Peitl, Barna
Döbrönte, Róbert
Drimba, László
Sári, Réka
Varga, Angelika
Németh, József
Pázmány, Tamás
and
Szilvássy, Zoltán
2010.
Involvement of cholecystokinin in baseline and post-prandial whole body insulin sensitivity in rats.
European Journal of Pharmacology,
Vol. 644,
Issue. 1-3,
p.
251.
Zhang, Ruiling
Hao, Wei
Pan, Miao
Wang, Chuansheng
Zhang, Xiuli
Chen, Da Chun
Xiu, Mei Hong
De Yang, Fu
Kosten, Thomas R.
and
Zhang, Xiang Yang
2011.
The prevalence and clinical‐demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine.
Human Psychopharmacology: Clinical and Experimental,
Vol. 26,
Issue. 6,
p.
392.
Lipscombe, Lorraine L.
Lévesque, Linda E.
Gruneir, Andrea
Fischer, Hadas D.
Juurlink, David N.
Gill, Sudeep S.
Herrmann, Nathan
Hux, Janet E.
Anderson, Geoff M.
and
Rochon, Paula A.
2011.
Antipsychotic Drugs and the Risk of Hyperglycemia in Older Adults Without Diabetes: A Population-Based Observational Study.
The American Journal of Geriatric Psychiatry,
Vol. 19,
Issue. 12,
p.
1026.
Sejima, Ei
Yamauchi, Atsushi
Nishioku, Tsuyoshi
Koga, Mitsuhisa
Nakagama, Kengo
Dohgu, Shinya
Futagami, Kojiro
and
Kataoka, Yasufumi
2011.
A Role for Hypothalamic AMP-Activated Protein Kinase in the Mediation of Hyperphagia and Weight Gain Induced by Chronic Treatment with Olanzapine in Female Rats.
Cellular and Molecular Neurobiology,
Vol. 31,
Issue. 7,
p.
985.
DE HERT, MARC
CORRELL, CHRISTOPH U.
BOBES, JULIO
CETKOVICH‐BAKMAS, MARCELO
COHEN, DAN
ASAI, ITSUO
DETRAUX, JOHAN
GAUTAM, SHIV
MÖLLER, HANS‐JURGEN
NDETEI, DAVID M.
NEWCOMER, JOHN W.
UWAKWE, RICHARD
and
LEUCHT, STEFAN
2011.
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.
World Psychiatry,
Vol. 10,
Issue. 1,
p.
52.
Teff, Karen L.
and
Kim, Sangwon F.
2011.
Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.
Physiology & Behavior,
Vol. 104,
Issue. 4,
p.
590.
Hahn, Margaret
Chintoh, Araba
Giacca, Adria
Xu, Li
Lam, Loretta
Mann, Steve
Fletcher, Paul
Guenette, Melanie
Cohn, Tony
Wolever, Tom
Arenovich, Tamara
and
Remington, Gary
2011.
Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: An animal model.
Schizophrenia Research,
Vol. 131,
Issue. 1-3,
p.
90.
Davey, Kieran J.
O’Mahony, Siobhain M.
Schellekens, Harriet
O’Sullivan, Orla
Bienenstock, John
Cotter, Paul D.
Dinan, Timothy G.
and
Cryan, John F.
2012.
Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters.
Psychopharmacology,
Vol. 221,
Issue. 1,
p.
155.
De Hert, Marc
Detraux, Johan
van Winkel, Ruud
Yu, Weiping
and
Correll, Christoph U.
2012.
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
Nature Reviews Endocrinology,
Vol. 8,
Issue. 2,
p.
114.
Weston-Green, Katrina
Huang, Xu-Feng
Deng, Chao
and
Chang, Alice Y. W.
2012.
Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain.
PLoS ONE,
Vol. 7,
Issue. 3,
p.
e33548.
Tudhope, Susan J.
Wang, Chung-Chi
Petrie, John L.
Potts, Lloyd
Malcomson, Fiona
Kieswich, Julius
Yaqoob, Muhammad M.
Arden, Catherine
Hampson, Laura J.
and
Agius, Loranne
2012.
A Novel Mechanism for Regulating Hepatic Glycogen Synthesis Involving Serotonin and Cyclin-Dependent Kinase-5.
Diabetes,
Vol. 61,
Issue. 1,
p.
49.
Scheimann, Ann O.
2012.
Overview of paediatric obesity for the paediatric mental health provider.
International Review of Psychiatry,
Vol. 24,
Issue. 3,
p.
231.
Suzuki, Yutaro
Sugai, Takuro
Fukui, Naoki
Watanabe, Junzo
Ono, Shin
Tsuneyama, Nobuto
Saito, Mami
and
Someya, Toshiyuki
2012.
Quetiapine‐induced insulin resistance after switching from blonanserin despite a loss in both bodyweight and waist circumference.
Psychiatry and Clinical Neurosciences,
Vol. 66,
Issue. 6,
p.
534.
Dieset, Ingrid
Hope, Sigrun
Ueland, Thor
Bjella, Thomas
Agartz, Ingrid
Melle, Ingrid
Aukrust, Pål
Røssberg, Jan-Ivar
and
Andreassen, Ole A.
2012.
Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein.
Schizophrenia Research,
Vol. 140,
Issue. 1-3,
p.
169.
Bricker, Barbara
Jackson, Tanise
Boateng, Bernard
Zhu, Xue Y.
and
Ablordeppey, Seth Y.
2012.
Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats.
Pharmacology Biochemistry and Behavior,
Vol. 102,
Issue. 2,
p.
294.
Comments
No Comments have been published for this article.